Abstract
Toxoplasma gondii is a ubiquitous protozoan parasite that is responsible for severe congenital birth defects and fatal toxoplasmic encephalitis in immunocompromized people1. Fundamental aspects of obligate intracellular replication and pathogenesis are only now beginning to emerge for protozoan parasites. T. gondii has a fragmented pathway for salvaging pyrimidine nucleobases derived from the parasite or host cell, and this limited pyrimidine salvage capacity is funnelled exclusively through uracil phosphoribosyltransferase2,3. Disrupting the function of this enzyme does not affect the growth of T. gondii tachyzoites4, which suggests that the de novo pyrimidine biosynthesis pathway may be necessary for growth. We have examined the virulence of T. gondii mutants that lack carbamoyl phosphate synthetase II (uracil auxotrophs) to determine whether de novo pyrimidine biosynthesis is required in vivo. Here we show that T. gondii uracil auxotrophs are completely avirulent not only in immune-competent BALB/c mice but also in mice that lack interferon-γ. A single injection of the uracil auxotroph into BALB/c mice induces long-term protective immunity to toxoplasmosis. Our findings indicate the significance of the de novo pyrimidine biosynthesis pathway for the virulence of parasitic protozoa, and suggest routes for developing vaccines and chemotherapy.
Similar content being viewed by others
Main
Because of its genetic accessibility5,6,7 and natural virulence in mice, T. gondii is an excellent model for the discovery and evaluation of auxotrophic mutants that capitalize on differences in metabolism between protozoan parasites and their hosts. Like its host, T. gondii has an intact pathway for de novo pyrimidine biosynthesis, but differs in that it has only a limited pyrimidine salvage pathway (Fig. 1). In T. gondii, as in other parasites of the phylum Apicomplexa, the key regulatory enzyme of de novo pyrimidine biosynthesis is carbamoyl phosphate synthetase II (CPSII), a parasite enzyme that has distinctive properties compared with the CPSII activity of the mammalian host cell8. In addition, apicomplexan parasites have a monofunctional CPSII domain fused onto the same polypeptide as the glutamine amidotransferase domain, which produces an enzyme architecture that is not observed in bacteria, fungi or mammals9,10. These unique features of T. gondii CPSII make this activity an attractive target to disrupt to obtain null mutants.
We cloned a 6.6-kilobase (kb) HindIII CPSII genomic DNA fragment from strain RH that contains exons with significant similarity to CPSII from fungi, plants and mammals (Supplementary Information). The single chromosomal copy of this 6.6-kb HindIII fragment was disrupted to obtain uracil auxotroph strains cps1-1 and cps2-1. Neither strain had detectable CPSII activity compared with the activity measured in the wild-type RH strain (57 nmol h-1 mg-1). Without uracil supplementation the parasite invaded normally, but it failed to replicate once intracellular. Essentially, no growth was observed at uracil concentrations lower than 20 µM (Fig. 2a). Normal parasite growth was seen between about 0.2 and 0.6 mM uracil; however, growth was suppressed in uracil concentrations higher than 0.8 mM, which indicates that normal regulation of pyrimidine pools or salvage mechanisms may be disrupted in the auxotrophic mutants. The ability of added uracil to rescue this nonreplicating uracil auxotroph declined with time (Fig. 2b).
We verified that disruption of the CPSII gene was the genetic lesion responsible for the uracil auxotrophy of cps1-1 and cps2-1. Transfection of cps1-1 and cps2-1 with a linearized 6.6-kb CPSII HindIII fragment from the wild-type strain RH rescued significant numbers of parasites (scored as plaques), which then grew normally in the absence of uracil (Table 1). Rescued isolates (cps1-1rs) all had the wild-type RH CPSII genotype and phenotype on the basis of Southern blot (data not shown), CPSII activity (61 nmol h-1 mg-1 protein), and growth responses in uracil (Fig. 2a). In contrast, transfection of cps1-1 or cps2-1 with only plasmid DNA, or with the Δ6.6-kb CPSII HindIII plasmid containing an internal 1.1-kb BamHI-generated deletion failed to rescue any additional plaques in the absence of uracil (Table 1).
We tested the virulence of the T. gondii CPSII gene knockout mutants in a BALB/c mouse model of lethal toxoplasmosis. The parental RH strain is hypervirulent in all mice strains, with an estimated 100% lethal dose of fewer than 10 parasites11. Mice injected intraperitoneally with only a low dose of the parental wild-type RH strain succumb rapidly to the infection (median survival of 9 d). In contrast, mice injected with the cps1-1 or cps2-1 mutant survived the infection at inoculating doses of 103, 104, 105, 106 (data not shown) and 107 tachyzoites (Fig. 3a). Parasites could not be recovered from the intraperitoneal cavity of mice at 3 weeks after inoculation. Mice inoculated with the uracil auxotroph mutants survived longer than 12 months with no evidence of any phenotype of parasite persistence (tachyzoites or brain cysts). In contrast, parasites such as cps1-1rs, which were rescued by transfection of the uracil auxotroph mutants with the wild-type 6.6-kb CPSII HindIII fragment (Table 1), were highly virulent in BALB/c mice (Fig. 3a).
We examined the virulence of cps1-1 in homozygous interferon-γ (IFN-γ) knockout (gko) mice on a BALB/c background. Because the cytokine IFN-γ is necessary for host control of T. gondii infection, IFN-γ knockout mice rapidly succumb to toxoplasmosis even after infection with normally avirulent strains12. As expected, gko mice rapidly succumbed to the RH strain (median survival of 9 d; Fig. 3b). Unexpectedly, gko mice injected with the cps1-1 mutant survived the infection at inoculating doses of 103, 104, 105 (data not shown), 106 and 107 tachyzoites (Fig. 3b). The cps1-1-inoculated gko mice showed long-term survival (> 6 months), with no apparent phenotype of parasite persistence.
We examined whether the avirulent uracil auxotrophic mutants could protect mice from a lethal toxoplasma challenge infection. Groups of BALB/c mice were injected once with various doses of cps1-1 tachyzoites. These mice were injected 40 d later with a lethal challenge dose of strain RH. Parasite doses greater than 104 cps1-1 tachyzoites were highly effective in inducing a long-term protective immunity in BALB/c mice (Fig. 3c).
Our data indicate that the obligate intracellular T. gondii parasite may have evolved to have a strict reliance on its own de novo pyrimidine biosynthesis pathway in vivo. The parasite's pyrimidine salvage pathway cannot apparently salvage significant amounts of pyrimidines from its host cell. This adaptation of the protozoan parasite may have arisen as a consequence of the apparent low availability of pyrimidines in animal tissues13,14. Notably, the pyrimidine starvation phenotype of the cps1-1 and cps2-1 mutants results in a complete block of parasite replication in vitro (Fig. 2) and in vivo (Fig. 3). Identifying compounds that limit the de novo biosynthesis of pyrimidines in T. gondii might be a route for antiparasite drug design. The auxotrophic mutants described here are remarkably avirulent and can also induce long-term protective immunity to toxoplasmosis. To our knowledge, these are the first reported mutants of T. gondii that do not kill gko mice15. T. gondii elicits a strong cell-mediated immune response that controls its own growth and that can stimulate nonspecific resistance to unrelated pathogens and tumours16,17. Consequently, these auxotrophic mutants may offer even greater promise as a strategy for vaccine development. Developing pyrimidine auxotrophs in other protozoan parasites might verify drug targets in de novo pyrimidine biosynthesis and might also provide a broad-ranging approach to obtaining protozoan parasite mutants that are severely attenuated in their virulence.
Methods
Parasite culture and phenotypic analysis
Human foreskin fibroblasts (HFFs) were cultured in EMEM medium in 10% fetal bovine serum (FBS) at 37 °C in 95% air/5% CO2. We cultured parasites in EMEM in 1% FBS at 37 °C in 95% air/5% CO2. Plaques were visualized by fixing HFF monolayers in 50% (v/v) methanol and 7% (v/v) glacial acetic acid, and staining with saturated Coomassie blue dissolved in fixative. The CPSII enzyme assays were done as described8. We isolated parasite DNA and carried out Southern analysis as described18.
To determine whether added uracil could rescue intracellular mutants, replicate sets of flasks of confluent HFF cells were inoculated with 2 × 105, 2 × 104, 2 × 103 or 2 × 102 plaque forming units (p.f.u.) of uracil auxotroph tachyzoites. After a 3-h incubation at 37 °C in medium lacking uracil for attachment and invasion, the remaining extracellular parasites were removed (t = 0) by washing the monolayer with PBS, and cultures were incubated in medium lacking uracil. At various times, medium was removed from duplicate sets of the inoculated flasks and was replaced with medium containing 0.2 mM uracil. We stained monolayers and scored plaques by visual inspection 8 d after uracil addition.
Mutant construction and analysis
A genomic DNA fragment of the T. gondii CPSII gene (strain RH) was cloned using a polymerase chain reaction (PCR) signature homology strategy. A CPSII PCR DNA fragment of the expected size of 450 base pairs (bp) was isolated and subcloned into pBluescript. We examined 30 individual clones, each of which had an identical sequence with a high amino-acid similarity to other CPSII species. We used the 450-bp CPSII fragment to identify a single-copy 6.6-kb HindIII fragment of genomic DNA by Southern blot analysis and to screen a T. gondii HindIII plasmid library constructed in pBluescript to obtain the 6.6-kb CPSII HindIII clone. The Δ6.6-kb CPSII HindIII plasmid was constructed by creating a 1.1-kb BamHI deletion (deleting bp 2,261 to 3,347) in the central part of the 6.6-kb CPSII HindIII clone.
We made the targeting plasmid by inserting a dihydrofolate reductase/herpes simplex virus thymidine kinase/thymidylate synthase positive/negative selection marker18 adjacent to the 3′ CPSII sequences in the Δ6.6-kb CPSII HindIII plasmid. This plasmid was integrated into the CPSII locus by transfection18 of strain RH and selection in pyrimethamine with uracil supplementation. We screened clones derived from this selection for ones that grew normally in medium with 0.2 mM uracil, but had disrupted CPSII activity and could not plaque in medium lacking uracil. These cps1 and cps2 mutants were then subjected to negative selection in ganciclovir in the presence of uracil. This strategy selected parasites that lost expression of the integrated thymidine kinase marker18. We subcloned ganciclovir-resistant and pyrimethamine-sensitive parasites from this selection to produce T. gondii strains, cps1-1 and cps2-1. Uracil auxotrophs cps1-1 and cps2-1 have two tandem copies of the targeting plasmid integrated into the CPSII locus. Only the CPSII locus was disrupted, and integration was achieved by homologous recombination in CPSII sequences on the 5′ side of the BamHI sites of the 6.6-kb CPSII HindIII fragment (data not shown). We maintained the uracil auxotrophs in culture in medium supplemented with 0.2 mM uracil.
Murine virulence assay
We obtained tachyzoites by allowing infected HFF monolayers to lyse completely. Tachyzoites were purified by filtration through sterile 3-µm nuclepore membranes, washed in PBS and collected by centrifugation. We resuspended tachyzoites pellets in PBS and counted them under the microscope. Tachyzoites were injected intraperitoneally (i.p.) in 0.2 ml into mice aged 6–8 weeks. The actual p.f.u. in the inoculum was determined by plaque assay. In all of the mouse injection experiments and for all of the parasite strains tested, the p.f.u. to parasite ratio was between 0.4 and 0.6. We used four mice per parasite dose with each strain. Experiments with groups of mice were repeated twice. Mice were monitored for 40 d, and in some experiments for more than 1 year. We cared for mice according to NIH guidelines.
References
Luft, B. J. & Remington, J. S. Toxoplasmic encephalitis in AIDS. Clin. Inf. Dis. 15, 211–222 (1992).
Pfefferkorn, E. R. Toxoplasma gondii: the enzymic defect of a mutant resistant to 5-fluorodeoxyuridine. Exp. Parasitol. 44, 26–35 (1978).
Iltzsch, M. H. Pyrimidine salvage pathways in Toxoplasma gondii. J. Euk. Micro. 40, 24–28 (1993).
Donald, R. G. & Roos, D. S. Insertional mutagenesis and marker rescue in a protozoan parasite: cloning of the uracil phosphoribosyltransferase locus from Toxoplasma gondii. Proc. Natl Acad. Sci. USA 92, 5749–5753 (1995).
Soldati, D. & Boothroyd, J. C. Transient transfection and expression in the obligate intracellular parasite Toxoplasma gondii. Science 260, 349–352 (1993).
Donald, R. G. & Roos, D. S. Stable molecular transformation of Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria. Proc. Natl Acad. Sci. USA 90, 11703–11707 (1993).
Sibley, L. D., Messina, M. & Niesman, I. R. Stable DNA transformation in the obligate intracellular parasite Toxoplasma gondii by complementation of tryptophan auxotrophy. Proc. Natl Acad. Sci. USA 91, 5508–5512 (1994).
Asai, T. et al. Enzymes of the de novo pyrimidine biosynthetic pathway in Toxoplasma gondii. Mol. Biochem. Parasitol. 7, 89–100 (1983).
Flores, M. V., O'Sullivan, W. J. & Stewart, T. S. Characterisation of the carbamoyl phosphate synthetase gene from Plasmodium falciparum. Mol. Biochem. Parasitol. 68, 315–318 (1994).
Chansiri, K. & Bagnara, A. S. The structural gene for carbamoyl phosphate synthetase from the protozoan parasite Babesia bovis. Mol. Biochem. Parasitol. 74, 239–243 (1995).
Pfefferkorn, E. R. & Pfefferkorn, L. C. Toxoplasma gondii: isolation and preliminary characterization of temperature-sensitive mutants. Exp. Parasitol. 39, 365–376 (1976).
Suzuki, Y., Orellana, M. A., Schreiber, R. D. & Remington, J. S. Interferon-γ: the major mediator of resistance against Toxoplasma gondii. Science 240, 516–518 (1988).
Fields, P. I., Swanson, R. V., Haidaris, C. G. & Heffron, F. Mutants of Salmonella typhimurium that cannot survive within the macrophage are avirulent. Proc. Natl Acad. Sci. USA 83, 5189–5193 (1986).
Mahan, M. J., Slauch, J. M. & Mekalanos, J. J. Selection of bacterial virulence genes that are specifically induced in host tissues. Science 259, 686–688 (1993).
Scharton-Kersten, T. M. et al. In the absence of endogenous IFN-γ, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J. Immunol. 157, 4045–4054 (1996).
Mahmoud, A. A., Warren, K. S. & Strickland, G. T. Acquired resistance to infection with Schistosoma mansoni induced by Toxoplasma gondii. Nature 263, 56–57 (1976).
Charest, H. et al. Recombinant attenuated Toxoplasma gondii expressing the Plasmodium yoelii circumsporozoite protein provides highly effective priming for CD8+ T cell-dependent protective immunity against malaria. J. Immunol. 165, 2084–2092 (2000).
Fox, B. A., Belperron, A. A. & Bzik, D. J. Negative selection of herpes simplex virus thymidine kinase in Toxoplasma gondii. Mol. Biochem. Parasitol. 116, 85–88 (2001).
Bzik, D. J., Li, W. B., Horii, T. & Inselburg, J. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc. Natl Acad. Sci. USA 84, 8360–8364 (1987).
Acknowledgements
We thank members of the Bzik lab, and D. S. Roos, S. N. Fiering and E. R. Pfefferkorn for discussions. This work was supported by grants from the National Institutes of Health and the US Department of Defense.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Fox, B., Bzik, D. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature 415, 926–929 (2002). https://doi.org/10.1038/415926a
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/415926a
This article is cited by
-
A live attenuated RHΔompdcΔuprt mutant of Toxoplasma gondii induces strong protective immunity against toxoplasmosis in mice and cats
Infectious Diseases of Poverty (2023)
-
Parasites as potential targets for cancer immunotherapy
Journal of Cancer Research and Clinical Oncology (2023)
-
Phosphoglucomutase 1 contributes to optimal cyst development in Toxoplasma gondii
BMC Research Notes (2022)
-
In vitro maturation of Toxoplasma gondii bradyzoites in human myotubes and their metabolomic characterization
Nature Communications (2022)
-
Promising effects of parasite-derived compounds on tumor regression: a systematic review of in vitro and in vivo studies
Environmental Science and Pollution Research (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.